FY2024 EPS Estimates for Krystal Biotech, Inc. Cut by Analyst (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS) – Analysts at Chardan Capital cut their FY2024 EPS estimates for Krystal Biotech in a research report issued on Monday, November 6th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings of $1.62 per share for the year, down from their prior estimate of $2.75. Chardan Capital has a “Buy” rating and a $153.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is ($5.00) per share.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, November 6th. The company reported $2.79 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $3.89. The firm had revenue of $8.60 million for the quarter, compared to the consensus estimate of $6.29 million. During the same period last year, the company posted ($1.17) earnings per share. The business’s revenue was up 8500.0% compared to the same quarter last year.

A number of other research firms have also recently commented on KRYS. HC Wainwright reissued a “buy” rating and issued a $139.00 target price on shares of Krystal Biotech in a report on Monday, August 7th. Citigroup assumed coverage on shares of Krystal Biotech in a report on Thursday, October 12th. They issued a “buy” rating and a $160.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Krystal Biotech in a report on Tuesday. Finally, Berenberg Bank started coverage on shares of Krystal Biotech in a report on Thursday, September 7th. They issued a “buy” rating and a $154.00 price objective for the company. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $142.56.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $96.00 on Thursday. The firm’s fifty day moving average price is $116.82 and its two-hundred day moving average price is $115.37. Krystal Biotech has a one year low of $69.81 and a one year high of $132.68. The company has a market cap of $2.71 billion, a P/E ratio of -65.31 and a beta of 0.94.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, September 11th. The shares were sold at an average price of $127.23, for a total value of $3,180,750.00. Following the completion of the sale, the insider now owns 1,599,206 shares of the company’s stock, valued at approximately $203,466,979.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 17.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Large investors have recently bought and sold shares of the stock. Capital Impact Advisors LLC lifted its stake in Krystal Biotech by 5.7% during the 1st quarter. Capital Impact Advisors LLC now owns 5,726 shares of the company’s stock valued at $458,000 after acquiring an additional 307 shares in the last quarter. Harbor Capital Advisors Inc. raised its stake in shares of Krystal Biotech by 9.3% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 6,978 shares of the company’s stock worth $819,000 after purchasing an additional 595 shares during the period. ExodusPoint Capital Management LP raised its stake in shares of Krystal Biotech by 28.7% during the 1st quarter. ExodusPoint Capital Management LP now owns 136,141 shares of the company’s stock worth $10,899,000 after purchasing an additional 30,380 shares during the period. Handelsbanken Fonder AB raised its stake in shares of Krystal Biotech by 1.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 107,200 shares of the company’s stock worth $12,585,000 after purchasing an additional 2,000 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in shares of Krystal Biotech by 7.0% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,476 shares of the company’s stock worth $278,000 after purchasing an additional 227 shares during the period. 82.30% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis.